Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Assessing actionability and incidental findings of germline variants in two precision oncology trials.

European journal of cancer (Oxford, England : 1990) - 1 Oct 2024

Ibrahim Maria Baz, Adnani Yahia, Clément Gérôme Jules, Lacroix Ludovic, Loriot Yohann, Besse Benjamin, Massard Christophe, Rouleau Etienne

Abstract excerpt

INTRODUCTION: High-throughput sequencing techniques have revolutionized oncology. Paired germline-tumor DNA analysis has emerged as a comprehensive strategy to uncover actionable alterations in advanced cancer patients (ACP) enrolled in precision oncology trials. However, challenges persist in variant interpretation and managing incidental germline findings. METHODS: We conducted a study involving 288 ACP from...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Testing

Share to Germ-Line Mutation

Share to High-Throughput Nucleotide Sequencing

Share to Incidental Findings

Share to Neoplasms

Share to Precision Medicine

Source

Identifiers

PMID: 39154486
DOI: 10.1016/j.ejca.2024.114256

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Assessing actionability and incidental findings of germline variants in two precision oncology trials.PMID 39154486Read ↗

Germline Findings in Tumor-Only Sequencing: Points to Consider for Clinicians and Laboratories.Semantic proximity Read ↗

Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.Semantic proximity Read ↗

Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers.Semantic proximity Read ↗

Clinical Integration of Germline Findings from a Tumor Testing Precision Medicine ProgramSemantic proximity Read ↗

Precision Oncology: Who, How, What, When, and When Not?Semantic proximity Read ↗

Aligning Germline Cancer Predisposition With Tumor-Based Next-Generation Sequencing for Modern Oncology Diagnosis, Interception, and Therapeutic DevelopmentSemantic proximity Read ↗

Resources for Interpreting Variants in Precision Genomic Oncology ApplicationsSemantic proximity Read ↗

Germline pathogenic variants identification through Comprehensive Cancer Genome ProfilingSemantic proximity Read ↗

The Role of Next-Generation Sequencing in Precision Medicine: A Review of Outcomes in OncologySemantic proximity Read ↗

Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations.Semantic proximity Read ↗

Clinical Use of Precision Oncology Decision SupportSemantic proximity Read ↗

The Role of Next-Generation Sequencing in Precision Medicine: A Review of Outcomes in OncologySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.